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Abstract
The renin-angiotensin system (RAS) plays an important part in homeostasis through
angiotensin IPs role as a vasoconstrictor. Defects in the renin angiotensin system can lead to
hypertension, heart attack, and stroke (Weir, 1999). Studies have shown an inverse relationship
between Vitamin D3 and blood pressure (Li et al., 2002). While studies have been performed on
vitamin D's effect on renin expression, little is known about vitamin D's effect on the
angiotensin II high-affinity type 1 (ATi) receptor. The hypothesis for this study was that human
iliac artery endothelial cells (HIAEC) supplemented with 1,25-dihydroxy vitamin D3 will express
less AT] receptor protein expression than the control group. After exposing the cell to 1,25-
dihydroxy vitamin D3, RNA was isolated and RT-PCR was completed using AT| primers. Gel
electrophoresis allowed for quantification of expression by measuring the density of bands. Two
way ANOVA was used to determine significance, and it was determined that the presence of
1,25-dihydroxy vitamin D3 had no significant effect on either AT] or B-actin expression in HIAE
cells. The hypothesis can neither be rejected nor accepted however because the control group did
not express AT| and therefore it cannot be determined whether ATi expression would have been
reduced.
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Background
An important participant in maintaining homeostasis is the renin-angiotensin system
(RAS) which acts on blood pressure, electrolyte concentrations, and extracellular volume levels
(Kong and Li, 2003). The system is activated when the kidney releases renin into the blood in
response to physiological stimuli. Renin then converts angiotensinogen, released from the liver,
by cleaving it into the 10 amino acid polypeptide angiotensin I (ANG I) (Li, 2003). The
angiotensin-converting-enzyme (ACE) then in turn cleaves ANG 1 into angiotensin II (ANG II),
which acts on its cell membrane receptors in the kidney, heart, and brain to increase
vasoconstriction, to cause cell proliferation, and to stimulate the sympathetic nervous system (Li
et al., 2002). The biological effects ofANG II are mostly caused by binding to its high-affinity
type 1 receptor (AT|), which plays a role in vasoconstriction, cell proliferation, and
antinatriuresis (Weir, 1999 and Kong and Li, 2003). Both AT] and AT2 receptors are present on
myocytes, fibroblasts, endothelial cells, and vascular smooth muscle (Li et al., 1999a). Renin can
also be regulated by the feedback inhibition ofANG II (Kong and Li, 2003). Irregular RAS
activity is related to hypertension, heart attack, and stroke; therefore, understanding methods to
regulate RAS is an important objective in treating these conditions (Li et al., 2002).
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Fig 1. The Renin-Angiotensin System
In an attempt to control the RAS system, three classes of pharmaceuticals have been
developed: P blockers, ACE inhibitors, and angiotensin receptor blockers (Weir, 1999). Each
class has corresponding complications. ATi receptor blockers leave the other angiotensin
receptors unaffected and could lead to adverse effects in long-term use (Contreras et al., 2003),
while ACE inhibitors can be bypassed by alternative pathways (Weber, 1997). Because of the
difficulties associated with the pharmaceuticals used to treat irregularities in the RAS system,
other treatments are also being pursued. In recent clinical studies, an inverse relationship
between the Vitamin D concentration in plasma and blood pressure readings was established and
has led to further investigation of the use of Vitamin D in treatment for hypertension (Li et al.,
2002).
The majority of people obtain Vitamin D through solar UV-B radiation as a primary
source (Holick, 2006). Accumulating Vitamin D through dietary means is rare because few
dietary sources include significant amounts of Vitamin D (Holick, 2006). The few that do
include oily fish, egg yolks, fortified milk, and fish oils (Holick, 2006). Vitamin D consists of
two forms: Vitamin D2, which is formed from the irradiation of ergosterol in plants, and Vitamin
D3, which is produced in the skin after sunlight exposure (Holick, 2006). Vitamin D3 has been
the primary focus in research since studies revealed that an increase in UV irradiation resulted in
a decrease in blood pressure (Dakshinamurti and Dakshinamurti, 2001). There is also an increase
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in the frequency of hypertension with increased distance from the equator because the amount of
circulating Vitamin D3 fluctuates based on geographic location (Li et al., 2004).
In the body, exposure to UV radiation converts the chemical 7- dehydrocholesterol into
Vitamin D3 which is then transformed into 25-hydroxy vitamin D3 in the liver (Thibodeau and
Patton, 2007). Finally, the 25-hydroxy vitamin D3 is then transformed in the kidney to produce
the active form of Vitamin D, 1,25-dihydroxy vitamin D3 (Thibodeau and Patton, 2007).
Previously, it was thought Vitamin D's role in the body was limited to calcium homeostasis, but
because its receptors are found extensively throughout various types of tissue. Vitamin D is
believed to have other roles including ones in the immune system (Li, 2003).
Li's 2002 study provided evidence that 1,25-dihydroxy vitamin D3 functioned as an
endocrine suppressor to maintain the homeostasis of renin production thus lowering blood
pressure. Kong's 2003 study suggested that this repression is independent of the ANG II
feedback inhibition pathway. Further knowledge about Vitamin D's effect on the RAS system
can aid in treatment of conditions such as hypertension and alleviate the problems associated
with the current treatments. While most reports have been concerned with vitamin D on renin
expression, little is known about Vitamin D's effect on AT| receptor expression. By studying the
role of 1,25-dihydroxy vitamin D3 in vitro on the receptor expression, its role as a negative
regulator will be better understood. The hypothesis was that the human iliac artery endothelial
cells grown with 1,25-dihydroxy vitamin D3 will have decreased ATi receptor expression
compared to the control, indicating that vitamin D also affects expression of the receptor along
with renin activity. Results suggesting this interaction would help explain the observed inverse
relationship between blood pressure and vitamin D.
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Materials and Methods
Cells. Human iliac artery endothelial cells (HIAEC) were ordered from the American
Type Culture Collection (Catalog Number CRL-2608), plated in lOmL sterile flasks, and
incubated at 37°C in 95% air and 5% CO2 (Li et al, 1999b). The cells were plated with 10 mL of
F-12K modified medium (American Type Culture Collection Catalog No.30-2004) with 10%
fetal bovine serum added, 0.1 |iL of a 0.03 mg/mL solution of endothelial growth serum, and
0.01 |iL of a 0.1 mg/mL solution of heparin. The cells were grown to 80% confluency then split
into two 10 mL flasks. Third generation HIAEC were then split into seven 10mm dishes. The
media was replenished every second day.
Vitamin D treatment. One 1 0mm dish served as the control and therefore contained only
growth medium, heparin, and EGS. In another study, vitamin D was effective in enhancing
osteogenesis at the concentrations of 1 nM, 1 nM, and 1 00 nM, and therefore those were the
concentrations added to the growth media in the experimental groups (Malladi et al., 2006).
Concentrations of 1 nM, 10 nM, and 100 nM of la,25-dihydroxy vitamin D3 (Sigma D1530)
were added in addition to the growth medium in 2 dishes of cells per treatment. One dish per
treatment was treated for one hour, and the second dish was treated for four hours. Three trials
were completed. All dishes were collected at the same time using trypsin, and stored using
Qiagen's RNA Protect Cell Reagent in -20°C.
RNA isolation and spectrophotometry. RNA was isolated by using the Qiagen RNeasy
Plus Mini Kit (Catalog No. 74134). The spectrophotometer was used to inspect the quality of
RNA (260/280 nm) and determine the amount of each sample needed to run RT-PCR (Table 1).
RT-PCR. Using the Invitrogen Superscript II RT First-Strand Synthesis system for RT-
PCR (Cat No. 12371-019 Lot No. 1397500), reverse transcription was completed within a PTC-
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100 Programmable Thermal Controller thermocycler (MJ Research Inc) following the directions
provided using 4 |iiL of total RNA. The kit also contained the instructions to complete positive
and negative control reactions with 1 |iL of HeLa RNA. Polymerase chain reactions were
completed with both B-actin and AT| primers as the B-actin expression was used to standardize
ATi expression and ensure that procedures had been properly completed. Next, the Invitrogen kit
contained Taq DNA polymerase recombinant (Cat No. 10342-053 Lot No. 1368151) and all the
components needed to run the polymerase chain reaction which amplified the ATj and B-actin
strands within the thermocycler. PCR with ATi primers included 40 cycles of 94°C for 40
seconds, 55°C for 1 minute, and 72°C for 1 minute, and when running PCR with B-actin specific
primers, PCR consisted of 40 cycles at 95°C for 1 minute, 50°C for 1 minute, and 72°C for 1
minute (Li et al., 1999b).
Gel electrophoresis. Samples were then loaded into 0.7% agarose gels, along with a
positive and negative control provided by the Invitrogen kit and Invitrogen' s 1 kb ladder, and an
electrical current (110 volts) was passed through the gel to separate the DNA based on size. The
agarose gels contained ethidium bromide which would bind to all present DNA and would reveal
bands when inspected under ultraviolet light (Figure 2). ATi expression was expected to be
visualized at 532 bp and B-actin at 201 bp (Li et al., 1999b). The positive control was evident at
353 bp. Expression was quantified by measuring band densities (Gao et al., 2006). A polaroid
picture was then taken of each gel and scanned into a computer for analysis. The densities of the
bands were measured using Adobe Photoshop CS3 extended version 10.0. The images were
inverted, and the integrated densities were measured of the band and the background gel.
Integrated density is defined by Adobe as the sum of the values of the pixels in the selected area,
or the product of area and mean gray value. The integrated densities of the bands were divided
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by the integrated density of a random area of equal size of the same gel so that the densities
could be compared.
Statistical Analysis. The independent variable in this experiment is concentration of 1,25-
dihydroxy vitamin D3, and the dependent variable is ATi protein expression level. After
accounting for background density, the ratio of AT] density to B-actin was compared between
samples. Mean ratios of for concentrations of 1 nM, 10 nM, and 100 nM of vitamin D were
determined by compiling band density ratios of all trials (Table 2). These mean ratios were then
compared against the mean ratios from other treatments of vitamin D to observe any differences
with a standard deviation of 0.172 (Graph 1). The ratios of ATi to B-actin were run through a
two-way ANOVA test where a value of p <0.05 was considered to be statistically significant to
determine if 1, 25 dihydroxy vitamin D3 had any effect on ATi expression (Table 2). A two-way
ANOVA test was run with B-actin densities also to test for any effect (Table 3).
Results
Table 1 lists the 260/280 nm ratio for all of the samples. This was used to determine how much
of the sample was needed to run RT-PCR correctly, and the 260/280 nm ratio was used to
determine the quality of the RNA with 260/280nm of 2.00 indicating the best quality RNA.
Figure 2 contains the scanned gels that were used to determine the density of the bands of
expression. ATi expression would have been evident at 532 bp, while B-actin was obvious at 353
bp. By looking at Figure 3, it can be determined that there is not much variation in the mean
ratios of ATI to B-actin between test groups, and therefore the presence of vitamin D had little
effect. When the data was run through two-way ANOVA, there was a significance of 0.479 for
AT] expression (using AT] to B-actin ratios) and 0.683 for B-actin expression. Because neither
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significance is less than 0.05, 1,25 dihydroxy vitamin D3 made no significant difference on the
expression of either ATi or B-actin.
Table 1. Spectrophotometer readings
for RNA quality
Sample
RNA
concentration
(ng/microlitre)
260/280
nm
InM Ihr 10.30 1.57
lnM4hr 10.00 1.44
10 nM 1
hr 9.30 1.43
10nM4
hr 13.70 1.97
100 nM 1
hr 8.10 1.28
100 nM 4
hr 11.60 1.56
OnM 8.40 1.47
InM Ihr 7.10 1.48
lnM4hr 8.60 1.68
10 nM 1
hr 40.60 1.33
10nM4
hr 7.70 1.36
100 nM 1
hr 8.90 1.53
100 nM 4
hr 17.70 1.48
OnM 10.00 1.59
InM Ihr 5.30 1.68
lnM4hr 7.80 1.39
10 nM 1
hr 12.00 1.37
10nM4
hr 6.70 1.94
100 nM 1
hr 7.20 1.45
100 nM 1
hr 10.00 1.26
OnM 10.90 1.40
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Fig 2. Gel electrophoresis results of samples run on agarose gels. (A),
(C), (E) gels were samples that had ATi expression amplified. (B) (D)
(F) gels were amplified with B-actin primers.
Table 2. Integrated densities of B-actin and ATi bands of inverted gels for all treatment sannples and average ratios of
ATi to B-actin among treatment groups.
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Background
density
73827 73827
control density 0.56 0.24
B-actin gel
353 bp 15223 4139
background
density
17047 17047
control density 0.89 0.24
Trial 1
100
nM4
hr
10 nM
4hr
InM 4
hr
lOOnM
Ihr
10
nMl
hr
InM
Ihr
OnM
ATi bar
background
density
ATi density
23687
73827
0.32
31005
73827
0.42
45486
73827
0.62
46011
73827
0.62
40479
73827
0.55
48649
73827
0.66
56066
73827
0.76
B-actin bar
background
density
B-actin density
12041
17047
0.71
12812
17047
0.75
10898
17047
0.64
7521
17047
0.44
7441
17047
0.44
6551
17047
0.38
8747
17047
0.51
Ratio of ATi to B-
actin density
0.45 0.56 0.96 1.41 1.26 1.71 1.48
Trial 2
100
nM 4
hr
10 nM
4hr
InM
4hr
lOOnM
Ihr
10
nMl
hr
InM
Ihr
OnM
ATi bar
background
density
ATi density
28898
28737
1.01
28580
28737
0.99
28445
28737
0.99
28560
28737
0.99
28508
28737
0.99
28141
28737
0.98
28384
28737
0.99
B-actin bar 19572 23052 24029 23258 21314 23883 26349
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1
background
density
B-actin density
26506 26506 26506 26506
0.74 0.87 0.91 0.88
26506 26506 26506
0.80 0.90 0.99
Ratio of ATi to B-
actin density
1.36 1.14 1.09 1.13 1.23 1.09 0.99
Trial 3
100
nM4 10 nM InM 4 lOOnM
10
nMl InM OnM
hr
4hr hr Ihr
hr
Ihr
ATi bar 24794 24197 24325 24196 24259 22749 24199
background
density
24513 24513 24513 24513 24513 24513 24513
ATi density 1.01 0.99 0.99 0.99 0.99 0.93 0.99
B-actin bar 36591 36582 35915 36240 34461 14861 33409
background
density
38653 38653 38653 38653 38653 38653 38653
B-actin density 0.95 0.95 0.93 0.94 0.89 0.38 0.86
Ratio of ATi to B-
actin density
1.07 1.04 1.07 1.05 1.11 2.41 1.14
100
nM4
hr
10 nM
4hr
InM 4
hr
lOOnM
Ihr
10
nMl
hr
InM
Ihr
OnM
Average Ratio of
ATi to B-actin
density
0.96 0.92 1.04 1.20 1.20 1.74 1.21
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Figure 3. Inverted average ratios of ATi to B-actin density
among treatments
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Table 3. Two-way ANOVA Test of Between-Subjects Effects on ATi expression as measured by
ratio of ATi to B-actin
Dependent Variable: VAR00003
Source
Type III Sum
of Squares df
Mean
Square F Sig.
VAR00001 *
VAR00002 0.191 2 0.095
0.776 0.479
Table 4. Two Way ANOVA test of Between-Subjects Effects on B-actin band density
Dependent Variable: VAR00003
Source
Type III Sum of
Squares df
Mean
Square F Sig.
VAR00001 * VAR00002 0.038 2 0.019 0.392 0.683
Discussion
After running the integrated density data through the two-way ANOVA test, the
hypothesis is to be rejected because there is no significant difference after the treatment with
1,25-dihydroxy vitamin D3. The test was used to measure effects on either B-actin or ATi
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expression, but there was no significant difference in either. It can be assumed that procedure
was properly carried out because of the controls present throughout the experiment. Each trial
contained one dish of control cells to ensure the proper treatment of the cells, and there were no
indications of problems during incubation. There were some difficulties during treatments such
as condensation on some flasks and second trial cells being stressed due to a malfunction in the
delivery of CO2. These incidents however did not seem to affect the data in that cells with
condensation did not differ from other samples, and the data of the second trial does not conflict
with the data of the first or third trials. The spectrophotometer was used to confirm the presence
ofRNA before proceeding onto RT-PCR. During RT-PCR, the positive control did appear as a
strong band in the agarose gels. While the results of this experiment support the idea that 1,25-
dihydroxy vitamin D3 does not affect ATi expression, the control also did not express AT]
Previous research on the vitamin D- RAS relationship has been studied on lab rats which may
have made a difference. The cell line used in this experiment is human which may have led to
different results. Also perhaps in an organism AT] is required and would be expressed by arterial
cells as opposed to in vitro cells where the production of AT| would be energetically
unfavorable. To further support the findings of this experiment, it would be necessary to test the
effect of 1,25-dihydroxy vitamin D3 on a cell line or organism where ATi is normally expressed
in the control group. AT] receptor presence can be confirmed by the use of radiation binding
where the cells are exposed to radioactive ANG II. If the cells retain radiation after washing, the
cells used the ATi receptor to take in ANG II. If the ATi receptor is not present, cells can be
encouraged to take up the gene for the receptor by use of a vector. In endothelial cells of cardiac
tissue, the ATi receptor activation mediates major functional responses to ANG II, and the AT|
receptor expression is higher (Li et al., 1999a). Therefore, working with different cells lines such
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as human coronary artery endotheHal cells may reveal more. In this experiment, we were unable
to work with HCAE cells because of budget limitations, but there was no reason to believe that
working with HIAE cells would produce different results. Oxidized low density lipoprotein can
be used with human coronary artery endothelial cells to increase the expression of the ATi
receptor (Li et al., 2000). Therefore if all test groups were pretreated with ox-LDL before
exposure to 1,25 dihydroxy vitamin D3 there may be a measurable effect in ATi expression. In a
different study, rat pulmonary microvascular endothelial cells increased AT] expression with
lipopolysaccharide (LPS) treatment (Zhang and Sun, 2006). Pretreatment with angiotensin 11 in
rat pulmonary microvascular endothelial cells resulted in reduced ATi expression (Zhang and
Sun, 2006). Growth hormone has also been shown to increase the expression of the AT| receptor
in astrocytes (Wyse and Semia, 1997). It is also possible that the angiotensin II type 2 receptor
may have inhibited the expression of ATi by being an antagonist to the AT| receptor (AbdAlla et
al., 2001). Therefore it may be necessary to treat cells with an AT2 antagonist such as PD 123,3 19
before ATi expression can be measured (Ford et al., 1996). Another line of research that could
be followed would be to test the effects of 1 ,25-dihydroxy vitamin D3 on other components of the
RAS system. Most research has been focused on the effect on renin, and the results of this
experiment support no effect on ATi expression, but the other steps of the RAS system should
not be ignored and further research should be pursued.
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